Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis.
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Most antipsychotics are associated with weight gain and other metabolic complications. Several randomized trials have shown metformin to be effective, but this still hasn’t been included in clinical guidelines on managing antipsychotic induced weight gain. All double blind placebo controlled trials assessing the efficacy of metformin in the treatment of antipsychotic induced weight gain were included. Cochrane Central Register of Controlled Trials (CENTRAL) and MEDLINE were searched for the period January 2000-December 2015. Meta-analysis was carried out using the random effects model. Meta analysis of 12 published studies with a total of 743 patients found that in patients treated with antipsychotics, metformin treatment resulted in significantly better anthropometric and metabolic parameters than placebo. The mean change in weight was −3.27 kg (95 % CI −4.66 to −1.89) ( Z = 4.64, p < 0.001). Metformin compared to placebo resulted in significant reduction in BMI [−1.13 kg/m 2 (95 % CI −1.61 to −0.66)] and insulin resistance index [−1.49 (95 % CI −2.40 to −0.59)] but not fasting blood sugar [−2.48 mg/dl (95 % CI −5.54 to 0.57]. This meta-analysis confirms that metformin is effective in treating antipsychotic induced weight gain in patients with schizophrenia or schizoaffective disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Metformin (1000 mg total daily dose) and topiramate (100 mg/d) counteract the effects of some weight gain-promoting agents, particularly antipsychotics and can be considered as adjunctive therapy (topiramate: mean difference, −3.76 kg; 95% CI, −4.92 kg to −2.69 kg; metformin: mean difference, −3.27 kg; 95% CI, −4.66 kg to −1.89 kg).79,80”
From Obesity Management in Adults: A Review (2023) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“Meta-analysis was carried out using the random effects model of DerSimonian and Laird because the subjects and interventions in the studies have differed in ways that would have impacted on the results [24].”
MethodPreferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Encyclopedia of Psychology, Vol. 3. · doi:10.1037/10518-009 · Cited by 19,744
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582 · cited 3×
“The detailed risk of bias table is given as a additional file (Additional file 1: Table S1).”
MethodInfluentialZhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,540
Research works printed but not linked: 1
- The Nordic Cochrane Centre: Review Manager (RevMan) [ComputerProgram] Version 5.0. Copenhagen: The Cochrane Collaboration, Version 5.2.6 2012.
Cited by
Obesity Management in Adults: A Review
Elmaleh-Sachs, A., Schwartz, J. L., Bramante, C. T., Nicklas, J. M., Gudzune, K. A., & Jay, M. (2023) · JAMA · doi:10.1001/jama.2023.19897 · Cited by 813
Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications
Penninx, B. W. J. H., & Lange, S. M. M. (2018) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2018.20.1/bpenninx · Cited by 566
Metformin: Mechanisms in Human Obesity and Weight Loss
Yerevanian, A., & Soukas, A. A. (2019) · Current Obesity Reports · doi:10.1007/s13679-019-00335-3 · Cited by 414
Wei, G., Lu, K., Umar, M., Zhu, Z., Lu, W. W., Speakman, J. R., Chen, Y., Tong, L., & Chen, D. (2023) · Bone Research · doi:10.1038/s41413-023-00301-9 · Cited by 207
“Notably, some studies have reported that metformin, a medication used to treat diabetes, not only reduces body mass index (BMI) in obese individuals but also decreases the rate of joint replacement surgery in patients with OA 46 – 48 .”
BackgroundMazereel, V., Detraux, J., Vancampfort, D., van Winkel, R., & De Hert, M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.573479 · Cited by 205
Metadata
- Authors
- de Silva, V. A., Suraweera, C., Ratnatunga, S. S., Dayabandara, M., Wanniarachchi, N., & Hanwella, R.
- Affiliations
- National Hospital of Sri Lanka (LK)
- University of Colombo (LK)
- Venue
- BMC Psychiatry
- Published
- 2016-10-03
- Volume
- 16
- Issue
- 1
- Pages
- 341-341
- ISSN
- 1471-244X (ISSN-L)
- PMC
- PMC5048618
- OpenAlex
- W2529188573
- Cited by
- 227
- References
- 49
- Citations by year
- 2026: 15 · 2025: 35 · 2024: 34 · 2023: 29 · 2022: 29 · 2021: 28 · 2020: 15 · 2019: 23 · 2018: 11 · 2017: 8
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMC Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- This study did not receive any specific funding
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Social Sciences › Psychology › Clinical Psychology › Eating Disorders and Behaviors
- Keywords
- metformin, antipsychotic-induced weight gain, antipsychotic drugs, schizophrenia, schizoaffective disorder, insulin resistance, body mass index, fasting blood glucose, metabolic complications, weight loss
- MeSH terms
- Double-Blind Method, Humans, Metformin, Psychotic Disorders, Schizophrenia, Antipsychotic Agents, Weight Gain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1186/s12888-016-1049-5
- The paper
- de Silva, V. A., Suraweera, C., Ratnatunga, S. S., Dayabandara, M., Wanniarachchi, N., & Hanwella, R. (2016). Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry. https://doi.org/10.1186/s12888-016-1049-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.